ALRN - Aileron Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4085
-0.0365 (-8.20%)
At close: 4:00PM EDT

0.4100 0.00 (0.37%)
Pre-Market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous Close0.4450
Open0.4413
Bid0.0000 x 1400
Ask0.0000 x 4000
Day's Range0.4063 - 0.4451
52 Week Range0.4050 - 2.6000
Volume844,258
Avg. Volume452,046
Market Cap11.361M
Beta (3Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

    Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients. Company expects to present key findings of the phase 1b portion of this myelopreservation trial in the 2nd quarter of 2020.

  • GlobeNewswire

    Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification at the 2019 Congress of the European Society for Medical Oncology (ESMO) (Presentation Number: 475P). The reported safety results show that the combination has been very well-tolerated in the trial, with the most common non-hematological related adverse events grade ≤2 being nausea (46%) and fatigue (23%).

  • GlobeNewswire

    Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 24, 2019 -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients,.

  • GlobeNewswire

    Aileron Therapeutics Announces Management Change

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its current Chief Financial Officer, will be leaving Aileron effective September 13, 2019. All financial responsibilities are being transitioned to Richard Wanstall, who has served as the Company’s Vice President of Finance and Operations and principal accounting officer since 2018. “During this past year, we have built a strong leadership team with the hiring of Vojislav (Vojo) Vukovic, MD, PhD as Chief Medical Officer, Kathryn Gregory, MBA as Chief Business Officer, and the promotion of Allen Annis, PhD, as Senior Vice President of Research.

  • GlobeNewswire

    Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

    ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov.

  • GlobeNewswire

    Aileron Therapeutics Reports Second Quarter 2019 Financial Results

    Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified cancers ongoing and ahead of schedule. Interim.

  • GlobeNewswire

    Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

    ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov. Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including statements about Aileron’s clinical trials, financial prospects, future operations and sufficiency of funds for future operations, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019

    WATERTOWN, Mass., July 30, 2019 -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other.

  • GlobeNewswire

    Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ALRN-6924 as a myelopreservation agent in patients with p53-mutant cancers treated with chemotherapy. In preclinical studies ALRN-6924 has been shown to trigger a transient, dose-dependent cell-cycle arrest in normal bone marrow cells with normal p53. As others have shown, triggering cell-cycle arrest in rapidly dividing normal cells, such as bone marrow cells, can protect them from toxic effects of chemotherapy.

  • GlobeNewswire

    Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William (“Bill”) T. McKee and Josef (“Joe”) H. von Rickenbach have been elected to the Board of Directors, effective immediately. “We are very excited to have Bill and Joe, two industry executives with a tremendous breadth of experience and a strong track record of accomplishments, join our Board of Directors. “I believe Aileron’s stabilized cell-permeating peptide platform technology is very promising.  Aileron’s current clinical focus, combining ALRN-6924 with Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified tumors, along with its plans to commence a myelopreservation trial with ALRN-6924 in September for cancer patients receiving chemotherapy, both represent exciting opportunities.  Furthermore, I believe this platform is capable of producing additional novel drug candidates that address previously undruggable targets,” said Mr. von Rickenbach.

  • GlobeNewswire

    Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference

    ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov. Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including statements about Aileron’s clinical trials, financial prospects, future operations and sufficiency of funds for future operations, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    Aileron Therapeutics Reports First Quarter 2019 Financial Results

    Aileron announced a $26 million capital raise via PIPE transaction Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib).

  • GlobeNewswire

    Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8

    WATERTOWN, Mass., May 01, 2019 -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other.

  • GlobeNewswire

    Aileron Therapeutics Completes $26M Private Placement

    WATERTOWN, Mass., April 03, 2019 (GLOBE NEWSWIRE) --  Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today the closing of its previously announced private placement of Aileron common stock and warrants, resulting in gross proceeds of $26 million, before deducting placement agent fees and offering expenses, and excluding the exercise of any warrants. The private placement was led by Satter Medical Technology Partners, L.P. with significant additional participation from Jennison Associates (on behalf of certain clients) and an undisclosed institutional investor, in addition to other new and existing investors.

  • GlobeNewswire

    Aileron Therapeutics Announces Pricing of $26M Private Placement

    The private placement was led by Satter Medical Technology Partners, L.P. with significant additional participation from Jennison Associates (on behalf of certain clients) and an undisclosed institutional investor, in addition to other new and existing investors. The Company is selling in the private placement 11,838,582 units, consisting of 11,838,582 shares of common stock and associated warrants to purchase 11,838,582 shares of common stock, for a combined price of $2.01 per unit.  In addition, the Company is also selling in the private placement 1,096,741 units, consisting of pre-funded warrants to purchase 1,096,741 shares of common stock and associated warrants to purchase 1,096,741 shares of common stock, for a combined price of $2.01 per unit.

  • GlobeNewswire

    Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Kathryn Gregory has been named Chief Business Officer (CBO). In this role, Ms. Gregory will head Aileron's business development efforts, including global licensing, collaborations, transactions and alliances. “We are excited to expand our leadership team to include Kathryn Gregory as our Chief Business Officer as Kathryn will play an instrumental role in helping Aileron build value through its business development activities.  Kathryn will oversee our existing collaborations and spearhead the ongoing development of new partnerships,” said Dr. Manuel Aivado, CEO & President of Aileron.

  • ACCESSWIRE

    4 Healthcare Stocks Looking To Start February Off Strong

    With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • GlobeNewswire

    Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort intended to assess preliminary activity and safety of ALRN-6924 in combination with Pfizer’s palbociclib, also known as IBRANCE®, in cancer patients with MDM2-amplified solid tumors. “We are excited to launch this Phase 2a expansion cohort, expanding on our ALRN-6924 clinical trial combination program,” said Vojo Vukovic, MD, PhD, and Chief Medical Officer of Aileron.

  • GlobeNewswire

    Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting

    Results in relapsed/refractory peripheral T-cell lymphoma (PTCL) demonstrate single-agent clinical proof-of-concept Combination therapy dose-escalation with low-dose cytarabine.

  • GlobeNewswire

    Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers.  Overexpression of MDM2 in cancer is typically a driver of tumor proliferation.  Aileron expects this Phase 1B trial to start enrolling patients with solid tumors in the first quarter of 2019. ALRN-6924 is a first-in-class, stabilized cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt the interaction with both its endogenous inhibitors, MDMX and MDM2.  For p53 wild-type tumors, ALRN-6924 can restore p53-dependent tumor suppression.  Palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6.  The MDM2 and CDK4 genes are located on chromosome 12 in close proximity to one-another, with CDK4 very frequently co-amplified in the MDM2-amplification-positive patients to be enrolled in this trial.  This co-amplification further suggests a potential patient benefit from combining the MDM2/MDMX-inhibitor ALRN-6924 with the CDK4/6-inhibitor palbociclib1.

  • GlobeNewswire

    Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Aileron Therapeutics Reports Third Quarter 2018 Financial Results

    Manuel Aivado, MD, PhD, promoted to President and Chief Executive OfficerVojislav Vukovic, MD, appointed Senior Vice President, Chief Medical Officer, and Allen Annis, PhD,.

  • GlobeNewswire

    Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

    Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that Vojislav (Vojo) Vukovic, MD, PhD, has been named Chief Medical Officer (CMO). In addition, the Company announced the promotion of Allen Annis, PhD, to Senior Vice President of Research.

  • GlobeNewswire

    Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

    Investigator-Initiated Phase 1Trial of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer WATERTOWN, Mass., Nov. 01, 2018 -- Aileron Therapeutics (NASDAQ:ALRN), the.

  • GlobeNewswire

    Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018

    Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer and other diseases, today announced that the Company will report financial results for its third quarter ended September 30, 2018 on Wednesday, November 7, 2018 after the close of the market. Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeable alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. For more information, visit www.aileronrx.com, and for more information about our clinical trials please visit www.clinicaltrials.gov.